Non-Small Cell Lung Cancer Drugs: Market, Companies and R&D Outlook 2015-2025

LONDON, November 23, 2015 /PRNewswire/ --

Non-Small Cell Lung Cancer - Now Explore Potentials of New Drugs, Industry Changes and Emerging Opportunities

Are you interested in the future of lung cancer treatments? Our new analysis forecasts drug revenues for non-small cell lung cancer (NSCLC). There you find outlooks for sales growth. You also explore trends, results, R&D and opportunities, seeing commercial prospects.

Visiongain's report gives revenue predictions to 2025 at overall world market, submarket, product and national level. Avoid falling behind in data or losing influence. Instead discover, from 2015, what progress, opportunities and revenues those cancer drugs can achieve.

Read on, then, to explore that industry for lung cancer therapies and see what future revenue its expanding pharmaceuticals market could generate.

Predictions and other analysis to benefit your research, assessments, plans and decisions
The future looks promising for pharma companies treating those pulmonary cancers. New products enter that market and novel drug candidates reach late-stage clinical testing. Discover, from 2015, what revenues and other progress are possible.

Besides revenue forecasting to 2025, our new work shows recent results, sales growth rates and market shares. There you find original analysis. Assess research and development too, seeing outlooks. You also gain 83 tables, 49 charts and an interview with Novartis.

Our study's purpose is to help your research, analyses and decisions on non-small cell lung cancer, also benefiting your authority and reputation for commercial insight. Stay ahead.

Although no single report covers everything, the following sections show how our new investigation benefits your work.

Forecasts covering the overall world market and segments for treating that lung cancer
Discover in our new analysis revenue predictions to 2025 for NSCLC submarkets at world level. See what is possible for these four therapeutic classes:
• Chemotherapies
• EGFR and ALK inhibitors
• VEGF and VEGFR agents
• Immunotherapy.

Where lie the best sales potentials? With our survey you assess outlooks for revenue expansion, seeing where you can gain. Also investigate competitors' actions and outlooks.

That way you see how those cancer-treating medicines develop, hearing where needs and business opportunities exist. With a rising incidence of those lung cancers, the demand for better treatments will continue to bolster that industry and market. Discover what is possible.

You also find sales forecasts by product, exploring how those agents can succeed.

Predictions of leading products' sales - what is possible for those cancer-treating drugs?
How will individual NSCLC medicines perform from 2015 to 2025 at world level? Our study forecasts revenues of these 11 brands:
• Alimta (pemetrexed) by Eli Lilly
• Avastin (bevacizumab) by Roche
• Tarceva (erlotinib) by Roche
• Iressa (gefitinib) by AstraZeneca
• Gilotrif (afatinib) by Boehringer Ingelheim
• Xalkori (crizotinib) by Pfizer
• Abraxane (paclitaxel Protein-Bound) by Celgene
• Taxotere (docetaxel) by Sanofi
• Cyramza (ramucirumab) by Eli Lilly
• Zykadia (ceritinib) by Novartis
• Opdivo (nivolumab) by Bristol-Myers Squibb.

There you see how high sales can go, finding products and years with highest predicted revenues. You also examine competition. That way you investigate what is happening, understanding challenges, trends, competitors and opportunities.

Discover what the future holds for treating non-small cell lung cancer. Our work also shows you geographical predictions, by country.

National markets - what outlooks for those anticancer drug revenues?
Advances in the biopharma industry expand the range and use of medicines to treat NSCLC in developed and developing countries.

Our work shows you individual revenue forecasts to 2025 for 11 national markets:
• The United States
• Japan
• Germany, France, the United Kingdom, Italy and Spain (EU5 countries)
• Brazil, Russia, India and China (BRIC group).

That way you assess regions with highest revenues and potential sales growth. Explore outlooks for treating those diseases, including patients' and healthcare providers' needs.

You also examine developments leading to novel and improved NSCLC treatments.

R&D for those anticancer medicines - trends, innovations and progress
In our study you investigate that oncology - research and development on that pulmonary disease. You examine technological advances, exploring clinical trials and what they mean.

There, in particular, you find discussions of nine R&D pipeline candidates for non-small cell lung cancer:
• Alecensa (alectinib) by Roche
• Vargatef (nintedanib) by Boehringer Ingelheim
• AZD9291 by AstraZeneca
• Rociletinib (CO-1686) by Clovis Oncology
• Keytruda (pembrolizumab) by Merck (MSD)
• Ganetespib (STA-9090) by Synta Pharmaceuticals
• Halaven (eribulin) by Eisai
• Necitumumab by Eli Lilly
• Atezolizumab (MPDL3280A) by Roche.

Researchers' investigation of specific genetic mutations has led to the development of targeted therapies that offer greater hope for the treatment of the late-stage disease.

See, then, what is possible. R&D also gains momentum from rising disease prevalence and other forces making treatments for those pulmonary disorders more widely used.

Events and changes affecting companies treating that lung disease
Explore other issues, too, including these forces shaping the industry and market for that lung disorder:
• Genetic mutations allowing for targeted therapies, newer medicines offering improved treatment outcomes
• Treatment protocols by stage and for patient populations - maintenance, second-line and third-line therapies
• Regulators' views and cost-effectiveness - challenges and opportunities in drug approvals, pricing, reimbursement and healthcare budgets

To see a report overview please email Sara Peerun on [email protected]

• Recent approval for the NSCLC indication - expanding treatment options
• Overcoming patent expiries and competition from generic drugs
• Identification of biomarkers for targeted therapies, advancing treatment protocols.

You also gain SWOT analysis, assessing what drives and restrains that prominent, expanding anticancer drugs market.

See, then, what is possible for leading pharma companies and specialists in biological drugs and related biotechnologies for combating NSCLC.

Leading organisations and overall 2019 market value - what revenues are possible?
Our work predicts the world market for those drugs will reach $8.8bn in 2019. That industry will achieve revenue expansion from 2015 to 2025. With our analysis you discover how high sales can go, seeing what is possible for those drug companies.
 
That way you assess what organisations hold most potential. For NSCLC therapies you explore drug developers, producers and marketers serving those therapeutic needs.

You also gain an exclusive interview with Novartis. Discover what the future holds for companies in that market, exploring what they say and do, as well as their prospects.

7 ways Non-Small Cell Lung Cancer Drugs: Market, Companies and R&D Outlook 2015-2025 helps you
Our new investigation benefits your work in these seven main ways, helping you stay ahead in knowledge:
• Revenues for NSCLC drug therapies to 2025 - assess that overall world market's potential, seeing scope for investments, developments, production and marketing
• Submarket revenues to 2025 covering 4 therapeutic segments - explore treatment categories, seeing their sales outlooks from 2015
• Leading products' sales to 2025 - discover predicted revenues of 11 top brands, seeing how well those medicines can compete and succeed
• National market forecasting to 2025 for 11 countries in the Americas, Europe and Asia - explore the best regions for treatment demand, sales and growth
• R&D activities - see progress, trends and prospects in that oncological research and development, finding technological, clinical and commercial possibilities
• Companies, news and opinion - examine participants in that rising market, gaining insight to help you stay ahead and benefit your influence
• Analysis of what stimulates and restrains that industry and market - assess challenges and strengths there, helping you compete and gain advantages.

That analysis, by our in-house team in the UK, gives knowledge to benefit your research, plans, decisions and proposals. It shows data you find nowhere else, helping you succeed.

Gain predictions for treating NSCLC, getting information to help you stay ahead
With our independent study you explore products, companies, progress and possibilities. Discover the best commercial opportunities, as well as ways to help lung cancer patients.

Having that information means you are less likely to fall behind in knowledge or miss opportunity. Through your choice now, find how to save time and effort, also benefiting your plans, decisions, presentations, proposals and influence.

Try that study. Our investigation shows you data, trends, opportunities and forecasts for that expanding anticancer market. So avoid missing out - please get our new report here now.

To see a report overview please email Sara Peerun on [email protected]

To request an exec summary of this report please email Sara Peerun at [email protected] or call Tel: +44 (0) 20 7336 6100

Or click on https://www.visiongain.com/Report/1525/Non-Small-Cell-Lung-Cancer-Drugs-Market-Companies-and-R-D-Outlook-2015-2025

Organisations Mentioned in the Report 

Abbott

Abraxis

Actavis

American Cancer Society

American Society of Clinical Oncology

Amgen

Apotex

AstraZeneca

Biocad

Boehringer Ingelheim

Bristol-Myers Squibb

Celgene

Chiba University Hospital (Japan)

Chugai

Clovis Oncology

Committee for Medicinal Products for Human Use (CHMP)

Eisai

Eli Lilly

EMD Serono

European Commission

European Medicines Agency (EMA)

European Union (EU)

German Institute for Quality and Efficiency in Health Care (IQWiG)

Hospira

Merck (MSD)

Merck KGaA

Ministry of Health, Labour and Welfare (MHLW, Japan)

National Comprehensive Cancer Network (NCCN)

Novartis

Oanda

Oncologic Drugs Advisory Committee (ODAC)

Pfizer

Qiagen

Roche

Roche Molecular Systems Inc

Sanofi

Swiss Re

Synta Pharmaceuticals

Teva

The Court of Appeal (England)

The European Federation of Pharmaceutical Industries and Associations (EFPIA)

The High Court (England)

The National Health Service (NHS, England)

The National Institute for Health and Care Excellence (NICE)

US Court of Appeals

US Food and Drug Administration (FDA)

World Health Organization (WHO)

To see a report overview please email Sara Peerun on [email protected]

SOURCE Visiongain